The clock is ticking on Eli Lilly’s big Alzheimer’s gamble; Pluristem reaches terms on $30M investment from China group
Eli Lilly’s huge solanezumab study is almost done. The pharma company noted this morning that the last patient visit has been recorded in its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
